RV1729
/ J&J
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
July 02, 2015
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD
(clinicaltrials.gov)
- P1; N=48; Completed; Sponsor: Respivert Ltd; Active, not recruiting -> Completed
Trial completion • Biosimilar • Chronic Obstructive Pulmonary Disease
April 14, 2015
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 for up to 28 Days
(clinicaltrials.gov)
- P1; N=49; Completed; Sponsor: Respivert Ltd; Active, not recruiting -> Completed
Trial completion • Asthma • Biosimilar • Immunology • Inflammation
July 25, 2014
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 for up to 28 Days
(clinicaltrials.gov)
- P1; N=36; Recruiting; Sponsor: Respivert Ltd; Not yet recruiting -> Recruiting ; N=48 -> 36
Enrollment change • Enrollment open • Asthma • Biosimilar • Immunology
August 26, 2014
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD
(clinicaltrials.gov)
- P1; N=47; Recruiting; Sponsor: Respivert Ltd; Not yet recruiting -> Recruiting
Enrollment open • Biosimilar • Immunology
May 24, 2015
JNJ: Pharmaceutical Business Review
(J&J)
- Anticipated regulatory filing for COPD during 2020-2024
Anticipated regulatory • Immunology
1 to 5
Of
5
Go to page
1